BENLYSTA (belimumab)

Self-Administration – injectable 
Medical Administration – intravenous

Diagnosis considered for coverage: 
  • Indicated for the treatment of:
    • Patients aged 5 years and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy
    • Patients aged 5 years and older with active lupus nephritis who are receiving standard therapy
  • Limitations of Use: The efficacy of Benlysta has not been evaluated in patients with severe active central nervous system lupus. Use of Benlysta is not recommended in this situation
Coverage Criteria:

For diagnosis of SLE:

  • Dose does not exceed one of the following:
    • SC: 200 mg once weekly 
    • IV: 10 mg/kg at 2?week intervals for the first 3 doses and at 4?week intervals thereafter; AND
  • Patient meets one of the following:
    • Request is for Benlysta vials: Patient is 5 years of age or older
    • Request is for Benlysta autoinjectors and prefilled syringes: Patient is 18 years of age or older; AND
  • Diagnosis of active systemic lupus erythematosus (SLE); AND
  • Prescribed by or in consultation with a rheumatologist; AND
  • Autoantibody positive (i.e., anti-nuclear antibody [ANA] titer greater than or equal to 1:80 or anti-dsDNA level greater than or equal to 30 IU/mL); AND
  • Trial and failure, contraindication, or intolerance to two standard of care treatments for active SLE (e.g., antimalarials [e.g., Plaquenil (hydroxychloroquine)], corticosteroids [e.g., prednisone], or immunosuppressants [e.g., methotrexate, Imuran (azathioprine)]); AND
  • Currently receiving at least one standard of care treatment for active SLE (e.g., antimalarials [e.g., Plaquenil (hydroxychloroquine)], corticosteroids [e.g., prednisone], or immunosuppressants [e.g., methotrexate, Imuran (azathioprine)])

For diagnosis of active lupus nephritis:

  • Dose does not exceed one of the following:
    • SC: 400-mg dose (two 200-mg injections) once weekly for 4 doses, then 200 mg once weekly thereafter
    • IV: 10 mg/kg at 2?week intervals for the first 3 doses and at 4?week intervals thereafter; AND
  • Patient meets one of the following:
    • Request is for Benlysta vials: Patient is 5 years of age or older
    • Request is for Benlysta autoinjectors and prefilled syringes: Patient is 18 years of age or older; AND
  • Diagnosis of active lupus nephritis; AND
  • Prescribed by or in consultation with a nephrologist or rheumatologist; AND
  • Currently receiving standard of care treatment for active lupus nephritis (e.g., corticosteroids [e.g., prednisone] with mycophenolate or cyclophosphamide)
Reauthorization Criteria:

For diagnosis of SLE and active lupus nephritis:

  • Dose does not exceed the FDA label maximum dose; AND
  • Documentation of positive clinical response to therapy (e.g., decrease or stabilization of symptoms, improvement in functional impairment, decrease of corticosteroid dose, decrease in pain medications)
Coverage Duration:
  • Initial: 6 months
  • Reauthorization: 6 months
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.

Additional Information:
  • Recommended SC dose:
    • Adult Patients with SLE: 200 mg once weekly
    • Adult Patients with Lupus Nephritis: 400-mg dose (two 200-mg injections) once weekly for 4 doses, then 200 mg once weekly thereafter
  • Recommended IV dose:
    • Adult and Pediatric Patients with SLE or Lupus Nephritis: 10 mg/kg at 2?week intervals for the first 3 doses and at 4?week intervals thereafter
  • For SLE, if transitioning from intravenous therapy with Benlysta to subcutaneous administration, administer the first subcutaneous dose 1 to 4 weeks after the last intravenous dose
  • A patient with lupus nephritis may transition from intravenous therapy with Benlysta to subcutaneous therapy any time after the patient completes the first 2 intravenous doses. If  transitioning, administer the first subcutaneous dose of 200 mg 1 to 2 weeks after the last intravenous dose.
Policy Updates:
  • 9/4/2018 – New policy approved by P&T.
  • 6/1/2023 – Updated format and criteria for SLE. Addition of criteria for active lupus nephritis
References:
  • Benlysta Prescribing Information. GlaxoSmithKline LLC. Philadelphia, PA. February 2023. 
  • Per clinical consult with rheumatologist, October 4, 2017. 
  • American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Guidelines for referral and management of systemic lupus erythematosus. Arthritis Rheum. 1999 Sep;42(9):1785-96. 
  • American College of Rheumatology Guidelines for Screening, Case Definition, Treatment and Management of Lupus Nephritis. Arthritis Care Res (Hoboken). 2012 Jun; 64(6): 797-808. 
  • Fanouriakis A, Kostopoulou M, Alunno A, et al. Ann Rheum Dis 2019;78:736–745.

Last review date: June 1, 2023

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone